Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The main aim and overall objective of the study is to assess whether rituximab is
non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators
will test specific blood and MRI biomarkers that may contribute to future personalized
treatment for MS patients. Furthermore, the investigators want to evaluate the health
economic consequences of the two therapies.
Phase:
Phase 3
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Göteborg University Helse Forde Helse Stavanger HF Sorlandet Hospital HF St. Olavs Hospital Sykehuset i Vestfold HF Sykehuset Innlandet HF Sykehuset Ostfold Sykehuset Telemark University Hospital of North Norway University of Oslo Vestre Viken Hospital Trust